Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2010-01-20EMA Application withdrawn: Comfyde (carisbamate) — Janssen-Cilag International NV
EMA withdrew the application for Comfyde (carisbamate) by Janssen-Cilag International NV in epilepsy.
-
FDA approval · 2010-01-14FDA Approved: CLORAZEPATE DIPOTASSIUM — Supplemental Application (Aurolife Pharma LLC)
FDA approved a supplemental application for Clorazepate Dipotassium by Aurolife Pharma LLC, granting regulatory approval for this generic pr…
-
CLINICAL_TRIALS trial_result · 2010-01-13Clinical Trial Update: Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures [Phase 3]
Long-term follow-up study evaluating the safety and efficacy of levetiracetam in children with partial-onset seizures (Phase 3).
-
FDA approval · 2010-01-12FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2010-01-07FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for divalproex sodium submitted by Zydus Pharmaceuticals USA Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2010-01-06FDA Approved: VALPROIC ACID — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for valproic acid submitted by ANI Pharmaceuticals, Inc.
-
FDA approval · 2010-01-06FDA Approved: VALPROIC ACID — Supplemental Application (Xttrium Laboratories Inc.)
FDA approved a supplemental application for valproic acid from Xttrium Laboratories Inc., granting approval of a generic product.
-
FDA approval · 2010-01-04FDA Approved: ETHOSUXIMIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA has approved a supplemental application for ethosuximide submitted by PAI Holdings/PAI Pharma.
-
CLINICAL_TRIALS trial_result · 2009-12-31Clinical Trial Update: Atkins Plus KetoCal for Childhood Epilepsy [Phase 3]
Phase 3 trial of Atkins Plus KetoCal for childhood epilepsy has completed.
-
FDA approval · 2009-12-30FDA Approved: GABAPENTIN — Original Application (Exelan Pharmaceuticals, Inc.)
The FDA approves Exelan Pharmaceuticals, Inc.'s original application for gabapentin as a generic product.
-
FDA approval · 2009-12-15FDA Approved: PHENYTOIN SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for phenytoin sodium from Sun Pharmaceutical Industries, Inc., to modify/expand the drug's label…
-
FDA approval · 2009-12-15FDA Approved: CARBAMAZEPINE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Carbamazepine (generic) submitted by Chartwell RX, LLC.
-
FDA approval · 2009-12-15FDA Approved: PHENYTOIN — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for phenytoin submitted by Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS research · 2009-12-09Clinical Trial Update: Clinical Trial of Light Therapy for Epilepsy [NA]
An update on a clinical trial at University College London evaluating light therapy for epilepsy; the trial status is unknown.
-
FDA approval · 2009-12-08FDA Approved: LEVETIRACETAM — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved Mylan Pharmaceuticals' original application for a generic levetiracetam product (LEVETIRACETAM) for use in treating seizure…
-
FDA approval · 2009-12-02FDA Approved: FOSPHENYTOIN SODIUM — Original Application (West-Ward Pharmaceuticals Corp)
FDA approved the original application for fosphenytoin sodium (generic) from West-Ward Pharmaceuticals Corp, authorizing its use as an antic…
-
CLINICAL_TRIALS trial_result · 2009-12-01Clinical Trial Update: Effect of Brivaracetam in Photosensitive Epileptic Subjects [Phase 2]
Phase 2 trial evaluating Brivaracetam in photosensitive epilepsy subjects has completed; the report summarizes the study's safety and explor…
-
FDA approval · 2009-11-25FDA Approved: CARBAMAZEPINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Carbamazepine from Apotex Corp.
-
FDA approval · 2009-11-20FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Zarontin (ethosuximide) filed by Parke-Davis Div of Pfizer Inc under ANDA080258.
-
FDA approval · 2009-11-20FDA Approved: GABAPENTIN — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for gabapentin from BluePoint Laboratories, granting approval to market a generic gabapentin product…
-
FDA approval · 2009-11-18FDA Approved: CARBAMAZEPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Carbamazepine by Torrent Pharmaceuticals Limited to update labeling.
-
FDA approval · 2009-11-18FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Vimpat (lacosamide) to expand its approved indications.
-
FDA approval · 2009-11-18FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc. This action signifies an additional regulatory clearance rela…
-
FDA approval · 2009-11-16FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for Levetiracetam, expanding the product's approved formulation/indication.
-
CLINICAL_TRIALS trial_result · 2009-11-13Clinical Trial Update: Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903). [Phase 3]
A Phase 3 follow-up trial of levetiracetam (Keppra) as monotherapy in newly diagnosed epilepsy completed, with results posted in 2009.